Proton Pump Inhibitor Therapy for the Treatment of... : Journal of Clinical Gastroenterology (original) (raw)

ALIMENTARY TRACT: Original Articles

Proton Pump Inhibitor Therapy for the Treatment of Laryngopharyngeal Reflux

A Meta-Analysis of Randomized Controlled Trials

Department of Gastroenterology, First Affiliated Hospital to Science and Technology University of Henan, Luoyang, Henan, China

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website, www.jcge.com.

H.G., H.M., and J.W. designed the study and wrote the paper. H.G. and H.M. searched the databases, selected eligible trials, extracted data, and analyzed the data.

The authors declare that they have nothing to disclose.

Reprints: Jinliang Wang, MD, Department of Gastroenterology, First Affiliated Hospital to Science and Technology University of Henan, 24 Jinghua Road, Luoyang, Henan 471003, China (e-mail: [email protected]).

Received November 9, 2014

Accepted March 12, 2015

Abstract

Goals:

To compare the treatment effect of proton pump inhibitor (PPI) therapy and placebo for patients with laryngopharyngeal reflux (LPR).

Study:

PubMed, Cochrane Library, and EMBASE were searched from the date of conception to August 2014. Randomized controlled clinical trials (RCTs) were included in this meta-analysis if they compared the treatment response of PPI therapy and placebo among patients with LPR. The risk difference, the standard mean difference (SMD), and their corresponding 95% confidence intervals (CIs) were calculated for the endpoints evaluated.

Results:

Fourteen eligible RCTs with 771 participants were identified and analyzed in this meta-analysis. By pooling all eligible data, we found that patients treated with PPI therapy had a significantly higher response rate than those who received placebo (risk difference=0.15; 95% CI, 0.01-0.30). Compared with placebo, PPI therapy could also improve the total reflux symptom index significantly (SMD=1.65; 95% CI, 0.15-3.14), but results of the reflux symptom index varied for specific symptoms. However, PPI therapy did not show any advantage over placebo in the improvement of the reflux finding score (SMD=0.62; 95% CI, −0.96-2.19).

Conclusions:

In this meta-analysis of 14 eligible RCTs, we found that in patients with LPR, PPI therapy could improve reflux symptoms significantly compared with placebo.